IFN a 2b Human
IFN alpha 2b, IFNA, INFA2, MGC125764, MGC125765.
(b) Analysis by SDS-PAGE.
Description
IFN-a 2b Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 166 amino acids and having a molecular mass of 19400 Dalton. The difference between IFNA2A and IFNA2B is in the amino acid present at position 23. IFN-alpha 2a has a lysine at that position 23 while IFN-alpha 2b has arginine.
The IFN-alpha 2b gene was obtained from human leukocytes.
The IFN-a 2b is purified by proprietary chromatographic techniques.
Product Specs
IFN-alpha, produced by macrophages, possesses antiviral properties. It stimulates the production of protein kinase and oligoadenylate synthetase enzymes.
Recombinant Human IFN-a 2b, produced in E. coli, is a non-glycosylated polypeptide chain consisting of 166 amino acids. With a molecular weight of 19400 Daltons, it differs from IFN-alpha 2a by a single amino acid at position 23 (arginine in IFN-alpha 2b instead of lysine in IFN-alpha 2a). The IFN-alpha 2b gene originates from human leukocytes, and the protein is purified using proprietary chromatographic techniques.
Reconstitute the lyophilized IFN-alpha 2b in sterile 18 MΩ-cm H2O to a concentration of at least 100 µg/ml. Further dilutions can be made in other aqueous solutions.
Lyophilized IFN-alpha 2b remains stable at room temperature for 3 weeks but should be stored desiccated below -18°C. Upon reconstitution, store at 4°C for 2-7 days. For long-term storage, freeze at -18°C after adding a carrier protein (0.1% HSA or BSA). Avoid freeze-thaw cycles.
Greater than 98.0% purity as determined by:
(a) RP-HPLC analysis
(b) SDS-PAGE analysis
Protein content was quantified using two independent methods:
1. UV spectroscopy at 280 nm employing an absorbance value of 0.924 as the extinction coefficient for a 0.1% (1 mg/ml) solution. This value is calculated using the PC GENE computer analysis program for protein sequences (IntelliGenetics).
2. RP-HPLC analysis using a calibrated IFN-alpha 2b solution as a reference standard.
IFN alpha 2b, IFNA, INFA2, MGC125764, MGC125765.
MCDLPQTHSL GSRRTLMLLA QMRRISLFSC LKDRHDFGFP QEEFGNQFQK AETIPVLHEM IQQIFNLFST KDSSAAWDET LLDKFYTELY QQLNDLEACV IQGVGVTETP LMKEDSILAV RKYFQRITLY LKEKKYSPCA WEVVRAEIMR SFSLSTNLQE SLRSKE
Product Science Overview
Interferon-alpha 2b (IFN-α2b) is a type I interferon, a group of cytokines known for their antiviral, antitumor, and immunomodulatory properties. IFN-α2b is produced by recombinant DNA technology, making it a valuable therapeutic agent in the treatment of various viral infections and cancers.
IFN-α2b is a protein consisting of 165 amino acids. It is produced by recombinant DNA technology, where the human IFN-α2b gene is inserted into bacterial or mammalian cells, which then express the protein. The recombinant protein is purified and formulated for therapeutic use.
- Antiviral Activity: IFN-α2b inhibits viral replication by inducing the expression of antiviral proteins in host cells. It enhances the immune response against viral infections by activating natural killer (NK) cells and macrophages.
- Antitumor Activity: IFN-α2b has antiproliferative effects on tumor cells. It inhibits cell division and induces apoptosis (programmed cell death) in cancer cells. It also enhances the immune system’s ability to recognize and destroy tumor cells.
- Immunomodulatory Effects: IFN-α2b modulates the immune response by increasing the expression of major histocompatibility complex (MHC) molecules, enhancing antigen presentation, and promoting the differentiation of T-helper cells.
- Chronic Hepatitis B and C: IFN-α2b is used to treat chronic hepatitis B and C infections. It reduces viral load and improves liver function by enhancing the immune response against the hepatitis viruses.
- Cancer Therapy: IFN-α2b is used in the treatment of certain cancers, including melanoma, hairy cell leukemia, and renal cell carcinoma. It helps to slow the growth of cancer cells and boosts the immune system’s ability to fight cancer.
- Other Viral Infections: IFN-α2b is also used to treat other viral infections, such as human papillomavirus (HPV) and respiratory syncytial virus (RSV).
IFN-α2b binds to specific receptors on the surface of target cells, triggering a signaling cascade that leads to the activation of various genes involved in antiviral, antiproliferative, and immunomodulatory responses. The binding of IFN-α2b to its receptor activates the JAK-STAT signaling pathway, which results in the transcription of interferon-stimulated genes (ISGs) that mediate its biological effects.
Recent advancements in the development of IFN-α2b include the creation of long-acting formulations to improve its half-life and therapeutic efficacy. These formulations involve modifications such as the addition of polyethylene glycol (PEG) or fusion with other proteins to extend the duration of action and reduce the frequency of administration .
